Back to today’s briefing

Story perspectives

Eli Lilly's Foundayo Reduces Cardiovascular Events, Gains FDA Approval

4/16/2026

44 9 Full Breakdown

Summary

Story summary

Eli Lilly's obesity pill Foundayo reduced major cardiovascular events by 16% and lowered all-cause mortality by 57% versus insulin glargine in a late-stage trial.
The study enrolled 2,749 patients.
Foundayo received FDA approval for weight management and will seek approval for type 2 diabetes by the end of Q2 under a fast-track program.
The safety profile remains consistent with earlier studies, and no liver safety issues were reported.

1 of 1

Story summary

Eli Lilly's obesity pill Foundayo reduced major cardiovascular events by 16% and lowered all-cause mortality by 57% versus insulin glargine in a late-stage trial.
The study enrolled 2,749 patients.
Foundayo received FDA approval for weight management and will seek approval for type 2 diabetes by the end of Q2 under a fast-track program.
The safety profile remains consistent with earlier studies, and no liver safety issues were reported.